CONVOCATORIA CAS Nº 004-2013 - Municipalidad de La Molina
CONVOCATORIA CAS Nº 004-2013 - Municipalidad de La Molina CONVOCATORIA CAS Nº 004-2013 - Municipalidad de La Molina
CDC to be at least $3,500, making the annual healthcare cost for C. diff. inMaryland more than $31.2 million. 8• Several acute general hospitals in Maryland have reported either outbreaks or casesdue to Acinetobacter bacteria with high degrees of antibiotic resistance. Theoutbreaks have been serious, involving a total of several dozen inpatients.Acinetobacter, a group of small gram-negative bacteria, can cause pneumonia,bacteremia, wound infection, or urinary tract infection. 9 In recent years, strains ofAcinetobacter have been emerging that are resistant to nearly all known remedies,commonly known as multi-drug resistant (MDR). Treatment is limited to a very oldand very toxic drug. There are no new drugs in clinical development designed to treatinfections caused by these deadly bacteria.Public health laboratory capacity:A key factor in Maryland’s ability to detect, monitor and control antimicrobial resistance isits public health laboratory capacity. Across the nation, increasing cases of antimicrobialresistance are currently swamping the ability of each state's public health laboratory to keeppace. There has been limited funding in the past for antibiotic resistance education programsand surveillance, and even this limited funding is on the decrease. Approximately only halfof state public health labs can provide some basic resistance testing. Like many states,Maryland lacks the targeted technical ability to promptly detect and characterize emergingresistance patterns in a range of pathogens. Therefore, such resistant organisms continue tospread unrecognized and unimpeded throughout the state.8 Healthcare Cost and Utilization Project (HCUP) State Inpatient Databases (SID), Agency for HealthcareResearch and Quality, http://www.hcupnet.ahrq.gov/, cited in a July 28, 2008 communication from CDC toSenator Sherrod Brown.9 Clinical Alert, Maryland Department of Health and Mental Hygiene, Office of Health Care Quality, Vol.2, No. 2; Summer 2003.Updated December 28, 2009
- Page 5 and 6: PROCESO CAS Nº 005CONVOCATORIA PAR
- Page 7 and 8: PROCESO CAS Nº 007FUNCIONES PRINCI
- Page 9 and 10: PROCESO CAS Nº 009CONVOCATORIA PAR
- Page 11 and 12: PROCESO CAS Nº 011CONVOCATORIA PAR
- Page 13 and 14: PROCESO CAS Nº 013CONVOCATORIA PAR
- Page 15 and 16: PROCESO CAS Nº 015CONVOCATORIA PAR
- Page 17 and 18: PROCESO CAS Nº 017CONVOCATORIA PAR
- Page 19 and 20: PROCESO CAS Nº 019CONVOCATORIA PAR
- Page 21 and 22: PROCESO CAS Nº 021CONVOCATORIA PAR
- Page 23 and 24: PROCESO CAS Nº 023CONVOCATORIA PAR
- Page 25 and 26: PROCESO CAS Nº 025CONVOCATORIA PAR
- Page 27 and 28: PROCESO CAS Nº 027CONVOCATORIA PAR
- Page 29 and 30: PROCESO CAS Nº 029CONVOCATORIA PAR
- Page 31 and 32: PROCESO CAS Nº 031CONVOCATORIA PAR
- Page 33 and 34: PROCESO CAS Nº 033CONVOCATORIA PAR
- Page 35 and 36: PROCESO CAS Nº 035CONVOCATORIA PAR
- Page 37 and 38: PROCESO CAS Nº 037CONVOCATORIA PAR
- Page 39 and 40: PROCESO CAS Nº 039CONVOCATORIA PAR
- Page 41 and 42: PROCESO CAS Nº 041CONVOCATORIA PAR
- Page 43 and 44: PROCESO CAS Nº 043CONVOCATORIA PAR
- Page 45 and 46: PROCESO CAS Nº 045CONVOCATORIA PAR
- Page 47 and 48: PROCESO CAS Nº 047CONVOCATORIA PAR
- Page 49 and 50: PROCESO CAS Nº 049CONVOCATORIA PAR
- Page 51 and 52: PROCESO CAS Nº 051CONVOCATORIA PAR
CDC to be at least $3,500, making the annual healthcare cost for C. diff. inMaryland more than $31.2 million. 8• Several acute general hospitals in Maryland have reported either outbreaks or casesdue to Acinetobacter bacteria with high <strong>de</strong>grees of antibiotic resistance. Theoutbreaks have been serious, involving a total of several dozen inpatients.Acinetobacter, a group of small gram-negative bacteria, can cause pneumonia,bacteremia, wound infection, or urinary tract infection. 9 In recent years, strains ofAcinetobacter have been emerging that are resistant to nearly all known remedies,commonly known as multi-drug resistant (MDR). Treatment is limited to a very oldand very toxic drug. There are no new drugs in clinical <strong>de</strong>velopment <strong>de</strong>signed to treatinfections caused by these <strong>de</strong>adly bacteria.Public health laboratory capacity:A key factor in Maryland’s ability to <strong>de</strong>tect, monitor and control antimicrobial resistance isits public health laboratory capacity. Across the nation, increasing cases of antimicrobialresistance are currently swamping the ability of each state's public health laboratory to keeppace. There has been limited funding in the past for antibiotic resistance education programsand surveillance, and even this limited funding is on the <strong>de</strong>crease. Approximately only halfof state public health labs can provi<strong>de</strong> some basic resistance testing. Like many states,Maryland lacks the targeted technical ability to promptly <strong>de</strong>tect and characterize emergingresistance patterns in a range of pathogens. Therefore, such resistant organisms continue tospread unrecognized and unimpe<strong>de</strong>d throughout the state.8 Healthcare Cost and Utilization Project (HCUP) State Inpatient Databases (SID), Agency for HealthcareResearch and Quality, http://www.hcupnet.ahrq.gov/, cited in a July 28, 2008 communication from CDC toSenator Sherrod Brown.9 Clinical Alert, Maryland Department of Health and Mental Hygiene, Office of Health Care Quality, Vol.2, No. 2; Summer 2003.Updated December 28, 2009